Orris

Explain in detail about congestive heart faliure

Reading File
Finding Sources
Finding Sources
Searching Images

congestive heart failure pathophysiology diagram

Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Searching Images

heart failure chest X-ray pulmonary edema

This anterior-posterior (AP) chest X-ray illustrates classic radiological findings of acute congestive heart failure. The primary finding is significant cardiomegaly, with the cardiac silhouette appearing enlarged and globular, occupying more than 50% of the thoracic diameter. Diffuse, bilateral hazy opacities are present throughout both lung fields, consistent with pulmonary edema. These opacifications are most prominent in the perihilar regions and lung bases, obscuring normal pulmonary vasculature and the sharp definition of the diaphragmatic borders. The costophrenic angles appear blunted, suggesting associated pleural effusions. Visible medical hardware includes ECG leads positioned on the chest wall. The image serves as an educational example of how chronic heart failure with reduced ejection fraction manifests as pulmonary venous congestion and interstitial-to-alveolar edema on diagnostic imaging.

This anterior-posterior (AP) chest X-ray illustrates classic radiological findings of acute congestive heart failure. The primary finding is significant cardiomegaly, with the cardiac silhouette appearing enlarged and globular, occupying more than 50% of the thoracic diameter. Diffuse, bilateral hazy opacities are present throughout both lung fields, consistent with pulmonary edema. These opacifications are most prominent in the perihilar regions and lung bases, obscuring normal pulmonary vasculature and the sharp definition of the diaphragmatic borders. The costophrenic angles appear blunted, suggesting associated pleural effusions. Visible medical hardware includes ECG leads positioned on the chest wall. The image serves as an educational example of how chronic heart failure with reduced ejection fraction manifests as pulmonary venous congestion and interstitial-to-alveolar edema on diagnostic imaging.

Posteroanterior (PA) view chest X-ray demonstrating clinical features of congestive heart failure and pulmonary edema. The image shows significant cardiomegaly with an enlarged cardiac silhouette. There is evidence of pulmonary venous hypertension, specifically characterized by upper lobe diversion where the vascular markings in the upper lobes are more prominent than those in the lower zones. The hilar regions appear congested with increased density and blurring of the hilar shadows. In the lower lung fields, patchy opacities and areas of increased density are visible, consistent with pulmonary consolidation or alveolar edema. The diaphragmatic angles appear somewhat obscured by the parenchymal density changes. This radiographic presentation is typical for decompensated heart failure, illustrating the redistribution of blood flow and fluid accumulation within the pulmonary parenchyma.

Posteroanterior (PA) view chest X-ray demonstrating clinical features of congestive heart failure and pulmonary edema. The image shows significant cardiomegaly with an enlarged cardiac silhouette. There is evidence of pulmonary venous hypertension, specifically characterized by upper lobe diversion where the vascular markings in the upper lobes are more prominent than those in the lower zones. The hilar regions appear congested with increased density and blurring of the hilar shadows. In the lower lung fields, patchy opacities and areas of increased density are visible, consistent with pulmonary consolidation or alveolar edema. The diaphragmatic angles appear somewhat obscured by the parenchymal density changes. This radiographic presentation is typical for decompensated heart failure, illustrating the redistribution of blood flow and fluid accumulation within the pulmonary parenchyma.

This diagnostic image is a posterior-anterior (PA) view chest X-ray demonstrating classic signs of congestive heart failure and acute pulmonary edema. Centrally, there is significant cardiomegaly with an increased cardiothoracic ratio, suggesting left ventricular enlargement. The pulmonary parenchyma shows widespread, bilateral increased opacification and haziness, particularly in the perihilar regions and lower lung zones, consistent with interstitial and alveolar edema. A black arrow in the right medial lung field specifically highlights enlarged, prominent pulmonary arteries and congested vascular markings (cephalization). The costophrenic angles appear partially obscured, which may indicate small pleural effusions. An implanted medical device, consistent with a chemotherapy port (Port-a-Cath), is visible in the right upper thoracic region with its catheter tip terminating in the superior vena cava. This visual evidence supports a clinical diagnosis of decompensated heart failure and pulmonary vascular congestion.

This diagnostic image is a posterior-anterior (PA) view chest X-ray demonstrating classic signs of congestive heart failure and acute pulmonary edema. Centrally, there is significant cardiomegaly with an increased cardiothoracic ratio, suggesting left ventricular enlargement. The pulmonary parenchyma shows widespread, bilateral increased opacification and haziness, particularly in the perihilar regions and lower lung zones, consistent with interstitial and alveolar edema. A black arrow in the right medial lung field specifically highlights enlarged, prominent pulmonary arteries and congested vascular markings (cephalization). The costophrenic angles appear partially obscured, which may indicate small pleural effusions. An implanted medical device, consistent with a chemotherapy port (Port-a-Cath), is visible in the right upper thoracic region with its catheter tip terminating in the superior vena cava. This visual evidence supports a clinical diagnosis of decompensated heart failure and pulmonary vascular congestion.

Reading File
Finding Sources
Searching Images

left ventricular hypertrophy cardiac remodeling heart failure

This diagnostic image is a standard transthoracic apical four-chamber view echocardiogram demonstrating advanced morphological changes secondary to pulmonary hypertension (PH). The visual focus is on the right heart structures, which exhibit significant remodeling due to chronic pressure and volume overload. Key findings include marked right ventricular (RV) hypertrophy, evidenced by thickened myocardial walls, and severe RV dilatation. The RV has lost its typical crescentic shape, appearing more spherical and globular. Furthermore, there is massive dilatation of the right atrium (RA), which appears disproportionately large compared to the left-sided chambers. These features—RV hypertrophy, spherical remodeling, and RA enlargement—are hallmark indicators of right heart failure and increased right ventricular wall stress. The image serves as an educational example of cardiac adaptation to increased pulmonary vascular resistance and chronic right heart afterload.

This diagnostic image is a standard transthoracic apical four-chamber view echocardiogram demonstrating advanced morphological changes secondary to pulmonary hypertension (PH). The visual focus is on the right heart structures, which exhibit significant remodeling due to chronic pressure and volume overload. Key findings include marked right ventricular (RV) hypertrophy, evidenced by thickened myocardial walls, and severe RV dilatation. The RV has lost its typical crescentic shape, appearing more spherical and globular. Furthermore, there is massive dilatation of the right atrium (RA), which appears disproportionately large compared to the left-sided chambers. These features—RV hypertrophy, spherical remodeling, and RA enlargement—are hallmark indicators of right heart failure and increased right ventricular wall stress. The image serves as an educational example of cardiac adaptation to increased pulmonary vascular resistance and chronic right heart afterload.

This clinical imaging figure consists of two side-by-side grayscale echocardiogram still frames focusing on the left heart chambers of a 63-year-old female patient. The diagnostic images illustrate key features of cardiovascular pathology associated with heart failure and atrial fibrillation. Centrally, the left ventricle is visible, showing moderately thickened myocardial walls consistent with left ventricular hypertrophy. The endocardial borders and chamber dimensions are delineated, reflecting decreased left ventricular diastolic function. While valve structures are partially visible, they are not the primary focus of these specific frames. The imaging serves as a clinical demonstration of the structural remodeling and hemodynamic changes seen in chronic cardiac conditions, including atrial fibrillation and congestive heart failure. These visual findings are relevant for medical students and clinicians studying cardiac ultrasound indicators like ejection fraction (LVEF) and ventricular geometry in the context of cardiovascular disease management.

This clinical imaging figure consists of two side-by-side grayscale echocardiogram still frames focusing on the left heart chambers of a 63-year-old female patient. The diagnostic images illustrate key features of cardiovascular pathology associated with heart failure and atrial fibrillation. Centrally, the left ventricle is visible, showing moderately thickened myocardial walls consistent with left ventricular hypertrophy. The endocardial borders and chamber dimensions are delineated, reflecting decreased left ventricular diastolic function. While valve structures are partially visible, they are not the primary focus of these specific frames. The imaging serves as a clinical demonstration of the structural remodeling and hemodynamic changes seen in chronic cardiac conditions, including atrial fibrillation and congestive heart failure. These visual findings are relevant for medical students and clinicians studying cardiac ultrasound indicators like ejection fraction (LVEF) and ventricular geometry in the context of cardiovascular disease management.

This diagnostic image is a transthoracic echocardiogram in a parasternal long-axis view, demonstrating significant structural cardiac abnormalities. The visual highlights include marked ventricular dilation and thickening of the ventricular walls, consistent with ventricular hypertrophy. An annotation in the upper left corner, 'Ao asc 3.4 cm', indicates a measurement of the ascending aorta's diameter. The cardiac chambers appear enlarged, and the myocardium exhibits increased echogenicity. This imaging provides evidence of chronic heart remodeling, often associated with systemic conditions such as systemic lupus erythematosus (SLE) or hypertensive heart disease, resulting in congestive heart failure. The image serves as a clinical example of structural heart changes secondary to long-term inflammatory or hypertensive disease, facilitating the study of cardiomyopathy and aortic root evaluation via ultrasound.

This diagnostic image is a transthoracic echocardiogram in a parasternal long-axis view, demonstrating significant structural cardiac abnormalities. The visual highlights include marked ventricular dilation and thickening of the ventricular walls, consistent with ventricular hypertrophy. An annotation in the upper left corner, 'Ao asc 3.4 cm', indicates a measurement of the ascending aorta's diameter. The cardiac chambers appear enlarged, and the myocardium exhibits increased echogenicity. This imaging provides evidence of chronic heart remodeling, often associated with systemic conditions such as systemic lupus erythematosus (SLE) or hypertensive heart disease, resulting in congestive heart failure. The image serves as a clinical example of structural heart changes secondary to long-term inflammatory or hypertensive disease, facilitating the study of cardiomyopathy and aortic root evaluation via ultrasound.

Reading File
Loading Image
I now have comprehensive material from multiple authoritative textbooks. Let me compile the full detailed response.

Congestive Heart Failure (CHF) - A Comprehensive Overview

Congestive heart failure (CHF) is a clinical syndrome in which the heart is unable to pump sufficient blood to meet the metabolic demands of the body, or can do so only at the cost of abnormally elevated filling pressures. "Congestive" refers to the resultant fluid backup (congestion) in the pulmonary and/or systemic venous circulation.

1. Definition and Types

CHF is not a single disease but a final common pathway for many cardiac disorders. It is broadly classified as:
By Ventricular Function:
  • Heart Failure with Reduced Ejection Fraction (HFrEF) - systolic dysfunction; EF < 40-45%. Cardiac output is significantly reduced. This is the classic form, seen after myocardial infarction.
  • Heart Failure with Preserved Ejection Fraction (HFpEF) - diastolic dysfunction; EF may be normal (>60%), but stiff, hypertrophied myocardium impairs filling. Cardiac output is reduced despite a normal EF. Drug treatment differs from HFrEF.
  • High-Output Failure - a rare form where even increased cardiac output is insufficient for the body's demands (hyperthyroidism, beriberi, severe anemia, arteriovenous shunts).
By Side:
  • Left-sided CHF - pulmonary congestion predominates
  • Right-sided CHF - systemic venous congestion predominates
  • Biventricular (global) CHF - both sides fail
  • Katzung's Basic and Clinical Pharmacology, 16th Ed.

2. Etiology (Causes)

CategoryExamples
Ischemic Heart DiseaseMyocardial infarction, chronic ischemia (most common cause)
HypertensionChronic pressure overload
Valvular DiseaseAortic stenosis/regurgitation, mitral regurgitation
CardiomyopathyDilated, hypertrophic, restrictive
ArrhythmiasAtrial fibrillation (can cause cardiomyopathy when rate is uncontrolled)
Cor PulmonalePulmonary hypertension, COPD
Metabolic/ToxicThyroid disease, alcohol, chemotherapy (anthracyclines)
Congenital HDVarious structural defects
  • Robbins, Cotran & Kumar Pathologic Basis of Disease

3. Pathophysiology

3a. Cardiac Hypertrophy - The Initial Response

When the heart faces increased work (pressure or volume overload), myocytes enlarge (cellular hypertrophy). The pattern depends on the stimulus:
  • Pressure-overload hypertrophy (e.g., hypertension, aortic stenosis): New sarcomeres are assembled in parallel, expanding cross-sectional area → concentric hypertrophy with thick walls and a small cavity.
  • Volume-overload hypertrophy (e.g., mitral/aortic regurgitation): New sarcomeres are assembled in series → eccentric hypertrophy with dilation. The wall may look normal in thickness despite increased heart weight.
Left ventricular hypertrophy - pressure vs. volume overload. Transverse sections of hearts showing normal (center), pressure-hypertrophied (left - thick walls, small cavity), and hypertrophied-dilated (right - enlarged chamber)
Fig: Left ventricular hypertrophy. Left = pressure hypertrophy (thick walls); Center = normal; Right = hypertrophy with dilation (volume overload or failure). From Robbins Pathology.
Importantly, myocyte hypertrophy is NOT accompanied by a proportional increase in capillary density. This creates a supply-demand mismatch: the thickened wall becomes ischemic, especially in the subendocardium.
  • Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 499-500

3b. Neurohumoral Compensation - The Vicious Cycle

When cardiac output falls, the body activates compensatory mechanisms that are initially helpful but ultimately harmful in the long run:
1. Sympathetic Nervous System Activation
  • Baroreceptor reflex is reset at lower sensitivity in CHF
  • Increased sympathetic outflow → tachycardia, increased contractility, vasoconstriction
  • Vasoconstriction (also driven by angiotensin II and endothelin) increases afterload, which further reduces ejection fraction - a vicious cycle
2. Renin-Angiotensin-Aldosterone System (RAAS)
  • Reduced renal perfusion activates renin release
  • Angiotensin II causes vasoconstriction, promotes norepinephrine release, and stimulates aldosterone
  • Aldosterone → sodium and water retention → increased preload and volume overload
  • Angiotensin II also drives cardiac fibrosis and remodeling
3. Arginine Vasopressin (ADH)
  • Released from the posterior pituitary → free water retention, worsening volume overload
4. Natriuretic Peptides (BNP, ANP)
  • Released from ventricular myocytes under wall stress
  • Counteract the RAAS by promoting natriuresis and vasodilation
  • Clinically used as biomarkers: elevated BNP/NT-proBNP is diagnostic of CHF
  • Katzung's Basic and Clinical Pharmacology, 16th Ed., p. 334-335

3c. Cellular and Molecular Changes

With sustained failure, more damaging cellular events occur:
  • Beta-receptor downregulation: Prolonged sympathetic stimulation causes downregulation of cardiac β1 receptors, reducing the heart's ability to respond to catecholamines
  • Calcium handling abnormalities: SERCA (SR Ca²⁺-ATPase) function is impaired, reducing Ca²⁺ reuptake; RyR channels leak Ca²⁺ from the SR → impaired contraction and relaxation, and arrhythmias
  • Apoptosis: Elevated caspase activity from excessive β-adrenergic stimulation accelerates myocyte death
  • Cardiac Remodeling: Structural changes including dilation, fibrosis, and altered ventricular geometry. Myocytes develop characteristics of fetal myocytes. Connective tissue proliferation stiffens the heart.
  • Mitochondrial dysfunction: Energy production is impaired in the overworked heart
  • Potassium channel alterations: Predispose to life-threatening arrhythmias (a major cause of death in CHF)
  • Katzung's Basic and Clinical Pharmacology, 16th Ed., p. 334-335

4. Classification

ACC/AHA Staging (Braunwald's Heart Disease)

StageDescriptionCorresponds to NYHA
AAt high risk for HF but without structural disease or symptomsNone
BStructural heart disease but without signs/symptomsClass I
CStructural heart disease with prior or current symptomsClass I, II, or III
DRefractory HF requiring specialized interventionsClass IV

NYHA Functional Classification

ClassDescription
INo limitation. Ordinary activity does not cause symptoms
IISlight limitation. Comfortable at rest; ordinary activity causes symptoms
IIIMarked limitation. Comfortable at rest; less-than-ordinary activity causes symptoms
IVSymptoms at rest; unable to carry on any activity without symptoms
  • Braunwald's Heart Disease, A Textbook of Cardiovascular Medicine

5. Clinical Features

Left-Sided Heart Failure (Pulmonary Congestion)

  • Dyspnea on exertion - the cardinal symptom; reflects rising pulmonary venous pressure
  • Orthopnea - dyspnea when lying flat; relieved by sitting up (increased venous return overwhelms failing LV)
  • Paroxysmal Nocturnal Dyspnea (PND) - sudden awakening with breathlessness
  • Cardiac Asthma - bronchospasm from pulmonary edema
  • Cough - especially nocturnal; may produce frothy/pink sputum in acute pulmonary edema
  • Fatigue - reduced cardiac output with poor peripheral perfusion
  • Tachycardia
  • S3 gallop (ventricular filling sound) - indicates volume overload
  • Fine bibasal crackles on auscultation
  • Displaced apex beat (cardiomegaly)
Morphological changes in left-sided CHF:
  • Heart: LV hypertrophy and dilation; secondary LA dilation → atrial fibrillation risk; thrombus formation in atrial appendage
  • Lungs: "Heavy, wet lungs" - perivascular and interstitial edema; alveolar edema; heart failure cells (hemosiderin-laden macrophages in alveoli from extravasated red cells) are a hallmark; pleural effusions (serous transudates)
  • Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 500

Right-Sided Heart Failure (Systemic Venous Congestion)

Most often caused by chronic left-sided failure (most common cause), or by cor pulmonale (lung disease).
  • Peripheral edema - pitting edema of feet, ankles, legs; sacral edema in bedridden patients
  • Anasarca - generalized massive edema
  • Jugular venous distension (JVD)
  • Hepatomegaly - congestive hepatomegaly (tender, pulsatile liver)
  • Ascites - peritoneal fluid accumulation
  • Splenomegaly - with platelet sequestration
  • Nausea/anorexia - bowel wall edema impairs absorption
  • Azotemia - renal congestion
Morphological changes in right-sided CHF:
  • Liver: "Nutmeg liver" - congested red-brown pericentral zones around central veins with normal tan periportal regions; in severe/longstanding cases, cardiac cirrhosis can develop
  • Pleural/Pericardial/Peritoneal spaces: Transudative effusions; ascites
  • Subcutaneous tissues: Dependent pitting edema; anasarca
  • Kidneys: Greater fluid retention and azotemia than in left-sided failure
  • Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 501

6. Investigations

Imaging

Chest X-ray (CXR) - classic features:
  • Cardiomegaly (cardiothoracic ratio > 0.5)
  • Upper lobe blood diversion (cephalization of pulmonary vasculature)
  • Kerley B lines (interstitial edema in interlobular septa)
  • Perihilar "bat-wing" haziness (alveolar edema)
  • Bilateral pleural effusions (blunting of costophrenic angles)
AP chest X-ray showing acute congestive heart failure: cardiomegaly with enlarged globular cardiac silhouette, bilateral perihilar haziness consistent with pulmonary edema, and blunting of costophrenic angles from pleural effusions
PA chest X-ray in congestive heart failure: cardiomegaly, upper lobe diversion, congested hilar shadows, and patchy lower zone opacities consistent with alveolar edema
Echocardiography - the most valuable investigation:
  • Measures ejection fraction (differentiates HFrEF from HFpEF)
  • Assesses wall motion, valve function, chamber dimensions
  • Detects mural thrombosis
ECG - may show LVH, arrhythmias, ST changes, LBBB

Biomarkers

  • BNP / NT-proBNP - released from ventricular myocytes under wall stress; elevated levels confirm CHF diagnosis and track severity. A low value has high negative predictive value for ruling out CHF.
  • Troponin - elevated in acute decompensation
  • Renal function / Electrolytes - assess for cardiorenal syndrome
  • Thyroid function - screen for reversible cause

7. Management

Non-Pharmacological

  • Salt restriction (< 2g Na/day)
  • Fluid restriction in severe CHF
  • Regular aerobic exercise (physiologic hypertrophy with beneficial capillary density increase - unlike pathologic hypertrophy)
  • Weight monitoring (daily; > 2kg gain in 2 days = seek medical attention)
  • Smoking cessation, alcohol avoidance

Pharmacological - HFrEF (Systolic CHF)

The "Four Pillars" of modern CHF therapy:
1. RAAS Blockade
  • ACE inhibitors (e.g., enalapril, ramipril, lisinopril) - first-line in all patients with LV systolic dysfunction regardless of symptoms. Reduce LV size, improve EF, reduce hospitalizations, and prolong survival. Side effects: dry cough (~5%), angioedema, hyperkalemia, renal dysfunction.
  • ARBs (e.g., valsartan, losartan) - substitute when ACE inhibitor cough or angioedema occurs; similar efficacy.
  • ARNI - Sacubitril/Valsartan (Entresto) - preferred over ACE inhibitor or ARB when tolerated. Sacubitril inhibits neprilysin (which breaks down natriuretic peptides), augmenting beneficial natriuresis and vasodilation. CANNOT be combined with an ACE inhibitor (risk of angioedema from dual bradykinin accumulation).
2. Beta-Blockers (e.g., carvedilol, metoprolol succinate, bisoprolol)
  • Counteract the harmful long-term effects of chronic sympathetic activation
  • Reduce heart rate, prevent arrhythmias, reverse remodeling
  • Must be started low and uptitrated slowly; NEVER start in acute decompensation
  • Cornerstone therapy alongside ARNI/ACE inhibitor
3. Mineralocorticoid Receptor Antagonists (MRA)
  • Spironolactone / Eplerenone - block aldosterone; reduce fibrosis and remodeling; diuretic effect
  • Significant mortality benefit in Class II-IV HF
  • Monitor for hyperkalemia and renal function
4. SGLT2 Inhibitors (e.g., dapagliflozin, empagliflozin)
  • Originally developed for diabetes; now first-line in CHF regardless of diabetes status
  • Reduce hospitalizations and mortality via multiple mechanisms (glycosuria, natriuresis, hemodynamic effects, anti-inflammatory)
Diuretics - Not mortality-reducing, but essential for symptom relief:
  • Loop diuretics (furosemide, torsemide) - first-line for volume overload; reduce preload
  • Thiazides - can be combined for diuretic resistance
Digoxin - Inhibits Na⁺/K⁺-ATPase (the sodium pump) → indirect increase in intracellular Ca²⁺ → positive inotropy. Also slows AV conduction (useful in CHF with AF). Narrow therapeutic window; avoid in renal failure. Does NOT reduce mortality but reduces hospitalizations.
Hydralazine + Isosorbide Dinitrate - Alternative vasodilator combination; especially beneficial in Black patients who cannot tolerate ACE inhibitors/ARBs.
Ivabradine - Inhibits the If "funny current" in the SA node; slows heart rate without affecting contractility. Used when heart rate remains elevated (>70 bpm) despite beta-blocker.
  • Goldman-Cecil Medicine; Katzung's Basic and Clinical Pharmacology, 16th Ed.

Device Therapy

  • Cardiac Resynchronization Therapy (CRT/Biventricular pacing) - for patients with LBBB and EF <35%; synchronizes RV and LV contraction; improves LVEF and reduces mortality
  • Implantable Cardioverter-Defibrillator (ICD) - for primary prevention of sudden cardiac death when EF remains <35% despite optimal medical therapy
  • Ventricular Assist Device (VAD) - mechanical support as bridge to transplant or destination therapy in end-stage HF
  • Heart Transplantation - gold standard for Stage D (refractory) CHF

8. Complications

ComplicationMechanism
Atrial FibrillationLA dilation from elevated filling pressures; prevalence 10% (Class I) to 50% (Class IV)
Sudden Cardiac DeathVentricular arrhythmias from ion channel changes, ischemia, electrolyte disturbances
Cardiorenal SyndromeReduced renal perfusion + venous congestion → worsening renal function
Thromboembolic eventsStasis of blood in dilated chambers; risk of LV mural thrombus, stroke
Cardiac CirrhosisLongstanding severe right-sided CHF → centrizonal hepatic fibrosis
Pulmonary HypertensionChronic elevated pulmonary venous pressure → pulmonary arterial remodeling
Malnutrition / CachexiaBowel edema, poor absorption, increased catabolism
  • Braunwald's Heart Disease; Robbins, Cotran & Kumar Pathologic Basis of Disease

9. Prognosis

CHF carries a significant mortality burden:
  • ~50% of patients with Class IV symptoms die within 1 year
  • Major causes of death: sudden arrhythmic death and progressive pump failure
  • Prognostic markers: LVEF, NYHA class, BNP levels, renal function, serum sodium
  • Modern quadruple therapy (ARNI + beta-blocker + MRA + SGLT2i) has dramatically improved prognosis compared to older regimens

Summary at a Glance

Reduced Cardiac Output
        ↓
↑ Sympathetic / RAAS activation
        ↓
Tachycardia, vasoconstriction, Na+H₂O retention
        ↓
↑ Afterload + ↑ Preload
        ↓
Further pump failure → Remodeling → Apoptosis
        ↓
Pulmonary congestion (Left CHF) + Systemic congestion (Right CHF)
The understanding that CHF is driven by neurohumoral activation (not just reduced pumping) is the basis for modern therapy: blocking the sympathetic system (beta-blockers), RAAS (ACE inhibitors/ARBs/ARNIs/MRAs), and augmenting natriuretic peptides (neprilysin inhibition, SGLT2i) rather than simply strengthening the heart's contractions.
This is a shared conversation. Sign in to Orris to start your own chat.